Although functional selectivity is now widely accepted, the molecular basis is poorly understood. We have studied how aspects of transmembrane region 5 (TM5) of the dopamine D 2L receptor interacts with three rationally selected rigid ligands (dihydrexidine, dinapsoline, and dinoxyline) and the reference compounds dopamine and quinpirole. As was expected from homology modeling, mutation of three TM5 serine residues to alanine (S5.42A, S5.43A, S5.46A) had little effect on antagonist affinity. All three mutations decreased the affinity of the agonist ligands to different degrees, S5.46A being somewhat less affected. Four functions [adenylate cyclase (AC), extracellular signal-regulated kinase 1/2 phosphorylation (MAPK), arachidonic acid release (AA), and guanosine 5Ј-O-(3-thio)triphosphate binding (GTP␥S)] were assessed. The intrinsic activity (IA) of quinpirole was unaffected by any of the mutations, whereas S5.42A and S5.46A mutations abolished the activity of dopamine and the three rigid ligands, although dihydrexidine retained IA at MAPK function only with S5.42A. Remarkably, S5.43A did not markedly affect IA for AC and MAPK for any of the ligands and eliminated AA activity for dinapsoline and dihydrexidine but not dinoxyline. These data suggest that this mutation did not disrupt the overall conformation or signaling ability of the mutant receptors but differentially affected ligand activation. Computational studies indicate that these D 2 agonists stabilize multiple receptor conformations. This has led to models showing the stabilized conformations and interhelical and receptor-ligand contacts corresponding to the different activation pathways stabilized by various agonists. These data provide a basis for understanding D 2L functional selectivity and rationally discovering functionally selective D 2 drugs.
Introduction
Functional selectivity is the phenomenon by which the binding of a ligand to a receptor results in markedly different levels of activation (or lack thereof) of one or several of the signaling pathways linked to the targeted receptor. Although this signaling bias runs counter to classic concepts of drugreceptor mechanisms, it has become firmly established and has been demonstrated for dozens of receptors (Urban et al., 2007; Neve, 2009) . As well as being heuristically interesting, it is also generally appreciated that functionally selective ligands with the "correct" bias may yield improved therapeutic indices versus drugs that are "typical" agonists or antagonists (Mailman, 2007) . It is generally believed that the functionally selected properties of a ligand are a result of the differential stabilization and/or induction of active states of the target receptor that are associated with specific signaling pathways (Kenakin, 1995 (Kenakin, , 2007 Urban et al., 2007) . However, there has been little exploration of how this may occur.
One of the earliest demonstrations of functional selectivity was with the dopamine D 2 receptor (Lawler et al., 1994 (Lawler et al., , 1999 . In particular, studies with a series of relatively rigid, conformationally restrained D 2 ligands showed extreme bias in signaling, in some cases as extreme as full agonist and pure antagonist (Mottola et al., 1991 (Mottola et al., , 2002 Kilts et al., 2002; Gay et al., 2004) . Thus, in Chinese hamster ovary (CHO) cells expressing hD 2L receptors, Gay et al. (2004) reported that dinapsoline (DNS) was a full agonist at several functions [e.g., fully inhibiting cAMP accumulation (AC) and fully stimulating p44/p42 MAP kinase phosphorylation (MAPK)] yet was a partial agonist at stimulating G protein-coupled inward rectifying potassium channels. Conversely, dinoxyline (DNX) was a full agonist at all four effector pathways . These data are noteworthy because there are only subtle differences in the chemical structures of DNS and DNX (see Fig. 1 ).
Subtle structural difference in a ligand may lead to functional selectivity Ryman-Rasmussen et al., 2005) . Thus, we hypothesized that modification of the D 2L receptor in regions where such ligands bind could be informative about the manner by which functionally selective signaling occurs. The current experiments address this hypothesis by studying the role of specific binding interactions that occur between the D 2L receptor and three rigid analogs, dihydrexidine (DHX) (Lovenberg et al., 1989) , DNS (Ghosh et al., 1996) , and DNX (Grubbs et al., 2004) . These ligands were originally designed as novel D 1 agonists in which the accessory phenyl ring was expected to confer both high D 1 affinity and high D 1 :D 2 selectivity (Nichols, 1983; Charifson et al., 1989; Mottola et al., 1996) . All three compounds also unexpectedly had significant D 2 affinity, leading to the discovery of D 2 functionally selective signaling for DHX and DNS Mottola et al., 2002; Gay et al., 2004 ).
In the current study, computational approaches were used to hypothesize specific binding interactions within each ligand-receptor complex. The affinity and functional properties of the probe and reference ligands was then assessed using four distinct functional endpoints. The resulting data are consistent with the hypothesis that subtle changes in ligand-specific interactions induced by mutation of selected amino acids of the receptor may stabilize and/or induce certain receptor conformations that lead to functional selectivity (i.e., differential activation of one or more signaling pathways).
Materials and Methods

Materials
Dinapsoline [(ϩ)8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de] isoquinoline], dinoxyline [(ϩ)8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de] isoquinoline], and dihydrexidine [trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a] phenanthridine] were synthesized according to published procedures (Brewster et al., 1990; Ghosh et al., 1996; Grubbs et al., 2004) . Dopamine, quinpirole, 3-isobutyl-1-methylxanthine, EDTA, dithiothreitol, sucrose, pepstatin A, leupeptin, PMSF, fetal bovine serum, and other standard chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO) and Sigma/ RBI (Natick, MA). [ (or [5,6,8,9,11,12,14,15- 
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I for cAMP assays was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA), and processed as described by Brown et al. (2009) . cAMP primary antibody was obtained from Dr. Gary Brooker (George Washington University, Washington DC); secondary antibody, rabbit anti-goat IgG, was purchased from Advanced Magnetics (Cambridge, MA). HEPES buffer was purchased from Research Organics (Cleveland, OH). Ham's F-12, Opti-MEM, penicillin, streptomycin, primers, and lipofectamine were purchased from Invitrogen (Carlsbad, CA). Hygromycin B was purchased from Roche Applied Science (Indianapolis, IN). Primary antibody to phospho-p44/p42 MAPK and secondary antibody, anti-rabbit horseradish peroxidase-conjugated, were purchased from Cell Signaling Technology Inc. (Danvers, MA).
Molecular Biology and Cell Culture
CHO hD 2L wild-type and mutant cells were maintained in Ham's F-12 media supplemented with 10% fetal bovine serum, 100ϫ penicillin-streptomycin, and 100 g/ml hygromycin. Mutant cell lines were constructed using the pcDNA5/FRT plasmid obtained from Invitrogen. After subcloning of the hD 2L receptor into the plasmid, point mutations were introduced using standard polymerase chain reaction techniques. Stable transfections of point mutants into CHO K1 cells were conducted using modifications of a previously published protocol (Milligan, 1999) . Throughout this article, the identification of the mutated amino acid residue will be made using universal notation proposed by Ballesteros and Weinstein (1995) 
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at ASPET Journals on June 24, 2017 molpharm.aspetjournals.org located, and the second number pair is the location of the residue under question relative to the most conserved residue for that helix. The residues we studied (listed in both universal notation and absolute position) were S5.42A (S193A), S5.43A (S194A), and S5.46A (S197A).
Radioreceptor Assays
Membranes for radioreceptor assays were prepared by rinsing cells with phosphate-buffered saline and then lysing with a solution containing 2 mM HEPES, 2 mM EDTA, 1 mM dithiothreitol, 1 g/ml pepstatin A, 0.5 g/ml leupeptin, and 0.05 g/ml PMSF. Cell fragments were scraped, homogenized, and centrifuged at 30,000g for 30 min. After centrifugation, cell pellets were resuspended, homogenized, and placed into storage buffer (50 mM HEPES, 0.32 M sucrose, 1 g/ml pepstatin A, 0.5 g/ml leupeptin, and 0.05 g/ml PMSF) and stored at Ϫ80°C. Saturation binding assays were conducted using protocols described previously 
GTP␥S Assay
Measurement of [
35 S]GTP␥S binding was determined as described previously (Shapiro et al., 2003) , with nonspecific binding defined by 10 M unlabeled GTP␥S. Assay tubes contained 150 to 200 pM [ 35 S]GTP␥S, binding buffer (50 mM HEPES, 100 mM NaCl, 4 mM MgCl 2 , 1 mM EDTA, 0.1% BSA, 0.1% ascorbic acid, pH adjusted to 7.4 with NaOH), 10 M GDP, and various concentrations of agonists and/or antagonist. Membranes (approximately 100 g protein/ml) were incubated with test compounds for 15 min at 30°C before addition of [
35 S]GTP␥S. After an additional 30-min incubation, the assay was terminated by filtration (Packard Filtermate 190 harvester; PerkinElmer Life and Analytical Sciences) with ice-cold wash buffer (50 mM HEPES and 4 mM MgCl 2 , pH adjusted to 7.4 with KOH), and radioactivity quantified by liquid scintillation spectrometry (Packard TopCount NXT; PerkinElmer Life and Analytical Sciences).
cAMP Accumulation Assay
Measurement of dopamine receptor agonist inhibition of forskolinstimulated cAMP accumulation was performed in whole-cell preparations as described previously . In brief, CHO cells were seeded in 24-well plates at a density of 2.5 ϫ 10 6 cells/well, and grown for 48 h in Ham's F-12 media supplemented with 10% fetal bovine serum and 100ϫ penicillin-streptomycin. Cells were preincubated for 5 min before in fresh media (serum-free media containing 25 mM HEPES, 500 M 3-isobutyl-1-methylxanthine, and 0.1% ascorbic acid) at 37°C. Assay medium then was aspirated, and fresh assay medium containing forskolin and/or various concentrations of the test compounds were added. The plates were incubated for 15 min at 37°C, and cells were rinsed with fresh assay medium and then aspirated; the reaction was halted using 0.1 N HCl. The cAMP was quantified using a modified radioimmunoassay described previously (Harper and Brooker, 1975) .
MAPK Assay
Measurement of dopamine receptor agonist stimulation of p44/p42 MAPK was performed in whole cell preparations by modifying a previously published protocol (Versteeg et al., 2000) . CHO cells were seeded in 96-well plates at a density of 5 ϫ 10 6 cells/well and grown for 48 h in Ham's F-12 media supplemented with 10% fetal bovine serum at 37°C. Cells were serum-starved for 6 h before stimulation. Appropriate drug dilutions of the test compounds were added to each well at a volume of 100 l for 10 min. The reaction then was terminated, and the cells fixed by aspirating the wells and adding 100 l of 4% formaldehyde PBS solution for 20 min. Cells were washed three times with 100 l of wash buffer (0.1% Triton X-100/ PBS solution), followed by a 20-min incubation with 0.6% H 2 O 2 Triton/PBS solution to quench endogenous peroxidases. After washing the cells three times again with wash buffer, and after a 1-h incubation with 10% BSA in Triton/PBS solution (to block nonspecific antibody binding), cells were incubated overnight (approximately 12 h) with a 1:250 dilution of PhosphoPlus p44/42 primary antibody (Cell Signaling Technology) in the Triton/PBS solution (100 l) containing 5% BSA at 4°C. Cells were washed three times with wash buffer for 5 min and then incubated with 100 l of horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:100 dilution) with 5% BSA at room temperature for 1 h. Again, cells were washed three times with wash buffer for 5 min and then twice with PBS. Cells were then incubated with 50 l of an o-phenylenediamine solution (0.4 mg/ml o-phenylenediamine, 17.8 mg/ml Na 2 HPO 4 ⅐7H 2 O, 7.3 mg/ml citric acid, and 0.015% H 2 O 2 ) for 15 min at room temperature in the dark. The reaction was terminated by the addition of 25 l of 1 M H 2 SO 4 that causes a light-to dark-orange color change (A 490 -A 650 ) that is proportional to phosphorylation.
Arachidonic Acid Assay
Measurement of dopamine receptor agonist potentiation of ATPstimulated [
3 H]AA release was measured in whole-cell preparations using modifications of a previously published method (Berg et al., 1998) . CHO cells were seeded in 24-well plates at a density of 5 ϫ 10 5 cells/well and grown for 24 h in Ham's F-12 media supplemented with 10% fetal bovine serum at 37°C. Cells are serum-starved with 500 l of serum-free Ham's F-12 containing 0.5 Ci/ml [ 3 H]AA for 5 h at 37°C. Ten-microliter aliquots were removed to compare with the original tritiated loading media to determine the time course and total cellular uptake of [ 3 H]AA. Cells were washed three times for 5 min each with Hanks' balanced salt solution containing 0.5% fatty acid-free BSA and antagonists for respective wells (500 l/well/ wash). Cells then were incubated with agonists for 15 min with or without ATP dissolved in Hanks' balanced salt solution/BSA (ATP being added last and in timed increments of 5 s between wells).
Data and Statistical Analysis
Data were analyzed using Prism 4.0/5.0 (GraphPad Software, San Diego CA). Saturation analysis was conducted using a one-site binding model (Prism). Competition data used nonlinear regression and a sigmoidal equation to determine IC 50 and E max values. The IC 50 values were corrected for radioligand concentration and are reported as corrected affinity values (K 0.5 ) adjusted by the Cheng-Prusoff equation for bimolecular interactions (Cheng and Prusoff, 1973) regardless of Hill coefficient (n H ). Intrinsic activity and potency estimates were made from sigmoidal fits of dose response data using Prism. Statistical analyses were conducted using SigmaStat 2.03 (Systat Software, Inc., San Jose, CA) or Instat 3 (GraphPad Software), using algorithms specified with each experiment.
identified from sequence alignment with other class A GPCRs. The homology model was predicted using the software MODELLER (http://salilab.org/modeller/) (Fiser and Sali, 2003) , followed by optimization of polar residues and energy minimization.
Ligand Docking. The agonist structures were modeled using the SCHRODINGER Maestro interface (Schrodinger LLC, Portland, OR). The ligand structures were optimized, and partial changes were calculated (QM, basis set 6-31G**) using the software Jaguar (Schrodinger LLC). Multiple conformations of the ligands were generated using Monte Carlo sampling (Macromodel, Maestro; Schrodinger LLC), and these conformations were docked into the D 2L receptor model using Glide standard precision module of Maestro. During docking, the van der Waals radii of both ligands and the receptor were scaled by 0.5 to increase diversity of the docked poses. The resulting ligand poses were clustered, and the top-ranking pose from each cluster was chosen based on binding energy. The final bound pose for each agonist was selected from these top ranking poses by visual inspection.
Ligand-Induced Receptor Conformational Changes. The ligand-induced receptor conformational change method has been discussed in detail previously (Bhattacharya et al., 2008b . Here we detail the steps of the method as applied to hD 2L . We identified that TM helices 3, 5, and 6 are in direct contact with all the agonists and hence would undergo conformational changes as a result of ligand binding. We performed simultaneous systematic spanning of the rotational orientation of TM helices 3, 5, and 6 in 10°increment with respect to the initial state. Although TM3, TM6 were rotated Ϯ50°, TM5 was rotated from Ϫ50°to ϩ20°. This process generated 968 receptor conformations. For each conformation, the following steps were performed.
• Optimization of all side-chain conformations using SCWRL 3.0 (http://dunbrack.fccc.edu/scwrl4/SCWRL4.php) (Canutescu and Dunbrack, 2003) .
• Conjugate gradient minimization of the potential energy of the ligand in the field of the rest of protein fixed until convergence of 0.3 kcal/mol-Å root-mean-square deviation in force per atom is achieved.
• Calculation of the ligand binding energy, defined as the difference of the potential energy of the ligand with protein fixed and the potential energy of the free ligand calculated in water using Generalized Born solvation method (Zamanakos, 2001 ).
• Interhelical and ligand-receptor hydrogen bonding using HB-PLUS 3.0 (http://www.biochem.ucl.ac.uk/bsm/hbplus/) (McDonald and Thornton, 1994) . This generates a three dimensional binding energy landscape in the rotational degrees of freedom of TMs 3, 5, and 6.
• Identification of all the local minima in this landscape and sorting of them by total number of interhelical hydrogen bonds (HB) and ligand-receptor HB and then by binding energy. The final ligand stabilized receptor structural model was selected based on low binding energy and high number of HBs.
Results
Ligand Rationale. For these studies, we compared the actions of the endogenous ligand dopamine and the prototypical D 2 agonist quinpirole with those of DHX, DNS, and DNX. The D 2 functional selectivity of dihydrexidine in vitro is consistent with both its D 2 functional selectivity in situ Mottola et al., 2002) and its lack of amphetamine-like behavioral actions (Darney et al., 1991) , despite being a full D 1 and D 2 agonist at the canonical signaling pathway. Of particular importance for the present study is the fact that dihydrexidine has a fused ring structure with no rotatable bonds. This relatively rigid structure decreases the degrees of freedom in interpreting data of the type this study was designed to generate. The second important ligand used was dinapsoline, another rigid compound that also has been shown to have functionally selective properties with the D 2 wild-type receptor . The third related ligand was dinoxyline, a compound that differs from dinapsoline only in an ether-methylene bridge substitution, a feature hypothesized to influence receptor interactions in subtle, but meaningful, ways. The structures of the eutomers of these compounds are shown in Fig. 1 . In all cases, the D 2 affinity of the distomer is at least 100-fold less than the eutomer at the wild-type D 2 receptor, and because of limited or unavailability of pure eutomer, racemic mixtures were used for this research. The reported K 0.5 values are based on the concentration of the racemate and were not corrected for the effects of the distomer. The synthetic ligands had no functional effect in any of these assays performed in wild-type CHO K1 cells not containing the D 2L receptor. The D 2 antagonist domperidone (10 M) was tested against WT and all receptor mutants; as expected, no functional activation was seen at any endpoint tested. Domperidone completely blocked quinpirole activation of all effector endpoints with both WT and mutant receptors.
Effect of S5.42A, S5.43A, and S5.46A Mutants on Receptor Expression and Antagonist Radioligand Binding. On the basis of the large body of data for aminergic GPCRs and of the D 2 receptor that elucidated many aspects of the role of TM5 serines in interaction with ligands (Strader et al., 1989; Cox et al., 1992; Mansour et al., 1992; Woodward et al., 1996; Wiens et al., 1998; Shi and Javitch, 2002) , we chose to explore the effects of the TM5 serine residues Ser5.42, Ser5.43, and Ser5.46 on the functional efficacy of the above-mentioned ligands for various signaling pathways. The hD 2L WT, S5.42A, S5.43A, and S5.46A receptors were expressed stably in CHO K1 cells and characterized by 1 , these mutations had only slight effects on the K D , ranging from 0.50 nM for S5.46A to 1.4 nM for S5.43A (WT 0.58 nM). The expression level also was similar for the WT, S5.42A, and S5.46A (2.3-4.0 pmol/mg of protein), whereas the S5.43A expressed at a somewhat higher density (20.7 pmol/mg of protein).
Effect of S5.42A, S5.43A, and S5.46A on Affinity of Agonist Probe Ligands. The affinity for each probe ligand was determined using competition radioreceptor assays versus [
3 H]N-methylspiperone in membranes from both WT and mutant receptors. An apparent affinity constant, K 0.5 (Table  1) , was determined from experimental IC 50 values corrected for radioligand K D and concentration using the bimolecular Cheng-Prusoff relationship (Cheng and Prusoff, 1973) . Competition binding studies also were conducted with several structurally distinct antagonists to rule out gross structural changes induced by the receptor (data not shown). Although all of the antagonists had slightly decreased affinity (as found for N-methylspiperone), the rank order of their affinity was unchanged, consistent with the hypothesis that these mutations caused no major changes to the overall receptor structure.
Representative data for each agonist probe ligand at each receptor are shown in Fig. 2 and summarized in Table 1 . It should be noted that although the differences between drugs was not always statistically significant when comparing the means (Table 1) , the rank order was identical in each of the experimental replicates. The differential effects that these mutations had on the rigid probe ligands are striking. For example, the S5.42A and S5.46A mutations caused a much greater loss of affinity to DNX than to the structurally similar DNS. These differential changes can be seen by comparing the rank orders of affinity.
• WT: DNX Ͼ DNS Ͼ quinpirole ϭ dopamine ϭ DHX.
Effect of Mutations on Ligand-Induced Gtp␥S Binding. An estimate of G protein turnover was conducted by assessing the ligand-induced binding of the nonhydrolyzable GTP analog [
35 S]GTP␥S ( Fig. 3 ; Table 2 ). As has been reported previously , DHX and DNS were partial agonists at stimulating GTP␥S binding, a property shared by DNX. The most remarkable finding in this experiment related to S5.43A. As noted above, this mutation caused a decrease in affinity of all of the ligands (Table 1; Fig.  2 ), yet the potency of the synthetic ligands in this assay was either unaffected or actually increased (significant for DNX). In addition, S5.43A actually increased the intrinsic activity of DNS. Conversely, S5.42A and S5.46A tended to cause a -11 -10 -9 -8 -7 -6 -5 -4 -11 -10 -9 -8 -7 -6 -5 -4 -11 -10 -9 -8 -7 -6 -5 -4 -11 -10 -9 -8 -7 -6 -5 -4 -11 -10 -9 -8 -7 -6 -5 -4 -11 -10 -9 -8 - Measurement of a second pathway, agonist stimulation and subsequent phosphorylation of the p44/p42 MAP kinase, was then conducted in a whole-cell assay system for WT and S5.42A receptors ( Fig. 4; Table 3 ; Supplemental Fig. 3 ). In the WT receptor system, all dopamine agonists (DNS, DNX, DHX, quinpirole, and dopamine) fully activated MAPK. S5.42A only minimally affected the actions of quinpirole (EC 50 , 44 nM) compared with WT (EC 50 , 23 nM). Conversely, the S5.42A mutation caused a complete loss of function at this endpoint for DNS and DNX and a partial loss of intrinsic activity for DHX.
Measurement of a third pathway, agonist-stimulated [ 3 H]arachidonic acid release, was conducted in a whole-cell assay system for WT and S5.42A ( Fig. 4 ; Table 3 ; Supplemental Fig. 4 ). The potency of quinpirole was decreased by the S5.42A mutation (EC 50 , 223 versus 63 nM in WT), but intrinsic activity was unaffected. Conversely, all of the other ligands were inactive with the S5.42A receptor (see Table 3 ). The MAPK and AA functional data provide strong evidence that functional effects caused by the S5.42A mutation are ligand-dependent and do not represent a general dysfunction of the receptor.
Functional Biochemical Differences Caused by S5.43A Mutant. The hypothesis that Ser5.43 is critical for forming intrahelical H-bonds that stabilize the TM5 ␣ helix 
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at ASPET Journals on June 24, 2017 molpharm.aspetjournals.org was tested using functional profiling as summarized in Fig. 4 and Table 3 . We hypothesized that mutation of S5.43A would have minimal effect on intrinsic activity at all endpoints measured with our test ligands. In support of that hypothesis, S5.43A had no effect on AC inhibition versus WT, although changes in rank order of potency were observed [WT: DNX Ͼ quinpirole Ͼ dopamine Ͼ DHX Ͼ DNS; S5.43A: quinpirole Ͼ dopamine Ͼ DNX Ͼ DNS Ͼ DHX (see Table 3 for EC 50 values)].
The MAPK data are shown in Fig. 4 , Table 3 , and Supplemental Fig. 3 . All of the test ligands (DNS, DNX, DHX, quinpirole, and dopamine) fully activated MAPK in both WT and the S5.43A mutant, although changes in rank order of potency were observed [WT: dopamine ϭ quinpirole ϭ DNX Ͼ DNS Ͼ DHX versus S5.43A: quinpirole Ͼ dopamine Ͼ DNS Ͼ DHX Ͼ DNX (see Table 3 for EC 50 values)]. The S5.43A mutation had dramatic effects on agonist stimulated [ 3 H]arachidonic acid release ( Fig. 4 ; Table 3 ; Supplemental Fig. 4) . With the mutant receptor, quinpirole and DNX were minimally affected, but activity of the other ligands was lost. It is noteworthy that the structurally similar ligands DNS and DNX were affected oppositely with S5.43A. These data indicate that the effects of the S5.43A mutation were seen primarily on one function (AA), but not on two others (AC, MAPK), at which the full agonist activity at the WT receptor was maintained.
Functional Biochemical Differences Caused by S5.46A. Ser5.46 is the TM5 serine residue located deepest in the binding pocket of hD 2L . The S5.46A mutation did not affect the inhibition of AC by quinpirole, whereas none of the other ligands retained activity. In a similar fashion, at both MAPK and AA release, the activity of DNS, DNX, DHX, and dopamine were absent with the S5.46A mutant. Quinpirole maintained its intrinsic activity, but had modest loss of potency (5-to 8-fold) at both functions.
Discussion
The rigid ligands used here were developed as D 1 agonists but were previously shown also to be functionally selective D 2 ligands both in heterologous systems Gay et al., 2004) and in situ Mottola et al., 2002) . They have atypical behavioral properties expected of canonical D 1 :D 2 agonists (Darney et al., 1991; Smith et al., 1997; Gulwadi et al., 2001 ). Thus, these ligands provide useful probes for our studies, and resulting hypotheses may explain novel actions of these compounds in vivo. Table 4 provides a nonquantitative summary of this study that will permit easier integration of these complex data. The S5.46A mutation caused a total loss of intrinsic activity for dopamine, dihydrexidine, dinapsoline, and dinoxyline but left quinpirole's intrinsic activity unaffected, suggesting that S5.46A did not disrupt the signaling ability. S5.43A mutation did not markedly affect the intrinsic activity of quinpirole at any function or affect the activity of DNX at any function, yet completely eliminated intrinsic activity for dopamine, dihydrexidine, and dinapsoline at AA release, but not other functions. Finally, S5.42A did not affect the intrinsic activity of quinpirole, but with one exception (DHX at MAPK) eliminated the intrinsic activity of dopamine and the rigid ligands. Functional selectivity also can be expressed as large and differential changes in potency as shown in Table 4 . A recent report showed that H6.55 mutations of the D 2L can abolish the bias of some functionally selective ligands (Tschammer et al., 2011 ), but the current study demonstrates that bias in a single function also can be introduced by a point mutation (Fig. 4) .
Strengths and Weaknesses of this Experimental System. It is now realized that GPCR functional selectivity may not only involve differential activation of G protein heterotrimers, but also many other interactors (Urban et al., 2007) . Thus, even in the same cell, the same receptor may be in- volved in different "signalsomes," and a measured endpoint may be dependent on activity of two or more signalsomes. Although it may seem desirable to have a totally defined system in which to study different ligand-induced/stabilized states, this is technically difficult, and no available system recapitulates the characteristics seen consistently in situ and in single native cells. Although we assume that mutation-induced functional selectivity is a consequence largely of alterations to the ligandreceptor interactions, it is possible that ligand-independent, mutation-induced alterations in the signalsome itself are involved. Two lines of evidence suggest this is not a major factor here. The reference ligand quinpirole has markedly different predicted docking poses compared with the D 2L receptor. In our assays, quinpirole-induced functional activity was similar in mutant and WT receptors, suggesting that functionally selective signaling of rigid ligands is not due simply to disruption of D 2 signaling. Moreover, in the current studies, the effects on intrinsic activity were often dramatic (e.g., 100% or 0% intrinsic activity), but if differential changes were occurring via two alternate routes, partial agonism might have been expected.
This raises an ancillary point. The S5.43A line had a much higher receptor expression than the WT, S5.42A, or S5.46A lines ( Table 1 ), suggesting that the failure to find partial agonism is a receptor reserve artifact. Yet partial agonism at GTP␥S binding, uncorrelated with receptor expression, was seen for all three rigid ligands. Indeed, the high expressing S5.43A increased the potency of DNX in stimulating GTP␥S binding, yet the same mutation markedly decreased DNX potency at adenylate cyclase. Thus, although receptor reserve may have influenced these results, the effect was probably minor. In the case of S5.43A, the mutation caused a major disruption only of a single function, and only for some ligands. Together, this suggests that the functional effects reflect alterations in ligand-receptor interactions and not gross disruption of receptor function.
Computational Analysis. As noted above, none of the mutations affected quinpirole activation, possibly because the full agonists (quinpirole, DA, DNS, DNX, and DHX) stabilize an ensemble of receptor conformations that show coupling affinities different from those of downstream proteins (Vaidehi and Kenakin, 2010) . To test this hypothesis, we computed the binding energy (BE) landscapes of the agonists and D 2L using the computational method of ligandinduced receptor conformational change that has been validated for prediction of activation of rhodopsin (Bhattacharya et al., 2008b) and ␤2-adrenergic receptor (Bhattacharya et al., 2008a; . As seen in Fig. 5C , the BE landscapes of dopamine shows two distinct minima (agonist states 1 and 2). The BE landscape of the other agonists are qualitatively similar (Supplemental Fig.  5 ). Small movements of TM3 and a counterclockwise rotation of TM5 (from the extracellular side) that brings Ser5.43 closer to the binding pocket characterize both minima. The difference between the two agonist-stabilized receptor conformations comes from TM6 movement. In receptor state 1, movement of TM6 brings His6.55 closer to TM5, whereas in state 2, TM6 movement brings His6.55 closer to TM7.
The agonist-preferred receptor conformations are stabilized by both interhelical and receptor-ligand contacts. Ser5.42 makes a hydrogen bond (HB) with the catechol hydroxyl groups of DA, DNS, and DNX (m-OH of DA, p-OH of DNS, DNX; Fig. 5 , B and E) in both agonist states 1 and 2. This HB is missing in the DHX-bound structure (distance, 5.8Å), and therefore Ser5.42 contributes toward the stability of the receptor active states of DA, DNS, and DNX, but to a lesser extent for DHX. This is in agreement with the functional selectivity profile of the S5.42A mutant, which completely abolishes activation of all pathways for all the agonists except DHX and quinpirole, which still maintains partial activity toward the MAPK pathway. In conjunction with the predicted DHX bind site, this suggests that Ser5.42 does not form an HB with DHX in the MAPK-specific D 2L conformation. The lack of HB with Ser5.42 could be compensated by stronger HB of DHX with the other two serines or tighter aromatic contact between the agonist and the phenylalanines on TM5 and TM6. This is not clear, however, from the models. Thus, S5.42A has less drastic effect on DHXmediated MAPK activation. In contrast to Ser5.42, the effect of Ser5.43 is more pathway-specific. In the activation assays, the S5.43A mutant only affected the AA pathway, whereas the other two pathways were unaffected for all agonists. For the AA pathway, S5.43A abolished the intrinsic activity of DA, DNS, and DHX and retained partial activity for DNX and quinpirole. In our model, the receptor/agonist state 1 is stabilized by an HB between Ser5.43 and His6.55 (Fig. 5B) . In contrast, the receptor/agonist state 2 is stabilized by the HB between His6.55 and Tyr7.35 (Fig. 5A ). Thus our model, in conjunction with the results from the S5.43A mutant, indicates that agonist state 1 may represent the receptor conformation that mediates AA activation, whereas slightly different agonist state 2 corresponds to the cAMP and MAPK activation, although this hypothesis will require further experimentation to test. In the DNX-and quinpirole-bound structures, the side chain of His6.55 is proximal to the ether oxygen of DNX and imidazole nitrogen of quinpirole, respectively. Thus, in the S5.43A mutant, DNX and quinpirole can stabilize agonist state 2 by forming HB with His6.55, whereas the other ligands (DA, DNS, DHX) that lack the polar motifs of DNX and quinpirole cannot form this HB and hence cannot stabilize state 1. These ligands require Ser5.43 to stabilize agonist state 1 and thus lose AA activity in the S5.43A mutant. This explains the insensitivity of S5.43A mutation toward DNX and quinpirole-mediated AA activation.
S5.46A eliminates activation of the three pathways for all agonists except quinpirole. In our agonist-stabilized model of the D 2 receptor, Ser5.46 forms a HB with Thr3.37 that stabilizes agonist states 1 and 2 (Fig. 5) . Thus mutating Ser5.46 to Ala destabilizes both the active states and abolishes activity of all the three pathways. Among the agonists studied here, quinpirole shows a different activation profile compared with the rest of the agonists. In the experimental activation assays, none of the serine mutations affected quinpirole-mediated D 2 activation. Unlike the catechol agonists, the nitrogen atoms on the imidazole of quinpirole are distant from the serine residues on TM5, precluding the strong HB with the serines in the agonist-stabilized states. This explains the insensitivity of the serine mutations toward quinpirole-mediated D 2 activation. To understand the mechanism of quinpirole activation, comparison of the interactions in the ligand-binding pockets in both the inactive and agonist-stabilized conformations showed that the n-propyl group of quinpirole is buried deep into the binding pocket, allowing direct contact with Trp6.48. The steric interaction could induce a change of rotamer of the Trp6.48 side chain, which in turn creates a steric clash with the side chain of Phe5.47 (Fig.  5F ). To relieve the clash between Trp6.48 and Phe5.47, TM5 rotates counterclockwise, leading to the activation of the receptor. Thus, Trp6.48 and Phe5.47 form an aromatic switch that stabilizes the active states of quinpirole-bound hD 2L . Our model also suggests that His6.55 is important for quinpirole-mediated AA activation, because the HB between quinpirole and His6.55 contributes to the stability of agonist state 1.
Differences in the agonist stabilized receptor conformations could lead to functional selectivity in the D 2L receptor. Selective conformational stabilization by structurally distinct agonists was reported in ␤ 2 -adrenergic receptor (Ghanouni et al., 2001; Swaminath et al., 2005) . Here we find that the three serine residues on TM5 interact differently with the agonist to stabilize distinct D 2L conformations for all agonists except quinpirole. The Ser5.46-Thr3.37 HB stabilizes the active state conformations of TM5, making Ser5.46 critical for all three activation pathways. In contrast, Ser5.43 stabilizes only one of the active states (AA pathway) by forming HB with His6.55. S5.42A shows different effects on the different agonists (less effect on DHX-MAPK activation) depending on the strength of the HB with various agonists. Besides the serines, the residue His6.55 is predicted to be important for the functionality of the D 2 receptor, and data to this effect were recently reported (Tschammer et al., 2011) . In ␤-adrenergic receptors, the residue in the analogous position of His6.55 (Asn6.55) has been shown to be important for agonist activity. In the ␤ 2 -adrenergic receptor, the N6.55L mutation reduced the activity of norepinephrine (Wieland et al., 1996) . In the agonist bound crystal structures of the ␤ 1 -adrenoreceptor (Warne et al., 2011) , Asn6.55 forms an HB with Ser5.43 similar to the predicted agonist-bound structures of the D 2 . In this work, His6.55 is predicted to stabilize the D 2 conformation responsible for AA activity by forming HB with Ser5.43 and polar groups of quinpirole and DNX. Unlike the serine mutations, which affect only the agonists with catechol motif, the H6.55A mutation is predicted to affect the activation of all agonists studied here, including quinpirole. The model of D 2 activation that emerges from this work is summarized in Fig. 6 . Although the computational model presented here explains the differences between AA versus cAMP/MAPK pathways, we attribute changes in functional selectivity to ligand-receptor interactions, but neglects effects on receptor-protein interactors. Thus, functional selectivity can be engendered by mutations that perturb arrestin binding (Lan et al., 2009a; Lan et al., 2009b) . Nonethe- less, our data demonstrate that ligand-receptor interactions can be a determinant of signaling bias, and the one clearly most relevant to drug discovery.
Conclusions
Antagonists were essentially unaffected by these TM5 serine mutations because their binding to the D 2 receptor, unlike that of agonists, is less dependent on interactions with these residues. The effects on the binding of these agonist ligands also were largely predictable by existing molecular models, whereas these mutations caused patterns of effects on the functional activity of the probe ligands not directly predictable from binding. One hypothesis is that ligands can cause receptor populations to shift between groups of discrete active states that are linked to specific signaling pathways. Alternatively, each ligand may induce a discrete range of conformational changes that affect, in a graded fashion, whether specific signaling pathways are activated. At present, the former hypothesis is one that has been largely favored and is the one that would explain the constitutive activity often seen in cellular systems. In any event, the ability to form and test hypotheses about how such changes occur can be heuristically interesting but also may lead to structure-based discovery of novel functionally selective ligands.
